Genomic instability resulting from homologous recombination DNA repair deficiency (HRD) is a response biomarker to assess ovarian and breast cancer patient eligibility for PARP inhibitor and platinum-based therapies. HRD measurements have the potential to improve cancer therapy, however standardizing and democratizing HRD measurements remains challenging. LGC SeraCare has developed HRD reference materials to support the development, validation, and routine determination of HRD status in cancer patients.
•Derived from tumor and matched-normal human cell lines
•Blended to ~65% tumor content with SNP-matched normal cell lines
#Genomic Instability Score (GIS) calculated using Illumina TruSight™ Oncology (TSO) 500 HRD RUO assay which calculates a GIS using an algorithm licensed from Myriad Genetics. Illumina TSO 500 HRD is not available in the U.S. or Japan.
*From 1x10 µm FFPE curl using QIAGEN QIAamp FFPE DNA Tissue Kit/Qubit DNA HS quant